AnaptysBio reports positive rosnilimab RA data; Q4 net loss narrows to $21.8M; cash $420.8M

ANAPTYSBIO, INC

2024-FY EPS reported -$5.12 revenue$91,280,000

Rosnilimab achieved statistical significance on primary endpoint (DAS28-CRP) at Week 12 in Phase 2b RA trial; highest-ever CDAI LDA responses reported.
Exclusive global license with Vanda for imsidolimab: $15M upfront, up to $35M milestones, 10% royalty on net sales.
Cash and investments $420.8M at Dec 31, 2024; cash runway reiterated through year-end 2027.
Collaboration revenue from GSK Jemperli milestones $43.1M in Q4 and $91.3M in FY2024; Jemperli 2024 sales $598M (>200% growth).
Net loss $21.8M in Q4 ($0.72 loss per share) vs $42.2M in prior year; FY2024 net loss $145.2M ($5.12 per share).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.